硼替佐米对淋巴瘤细胞株体外药物敏感性及临床意义的研究  

Sensitivity experiment of Bortezomib for lymphoma cell lines in vitro and its clinical significance

作　　者：陈新峰[1] 张明智[1] 张旭东[1] 岳光星[1] 曹玲[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052

出　　处：《医药论坛杂志》2012年第4期22-24,共3页Journal of Medical Forum

摘　　要：目的研究以7种人非霍奇金淋巴瘤(NHL)细胞株为实验对象,以细胞抑制率、半数抑制浓度(IC50)为指标,研究硼替佐米(Bortezomib,BZM)对7种淋巴瘤细胞株的体外敏感状况,从而为临床用药提供实验理论依据。方法 MTT法检测细胞抑制率,并计算半数抑制浓度IC50值。结果 7种淋巴瘤细胞株均对BZM敏感,但BZM对不同淋巴瘤细胞株的敏感性存在差异。结论 BZM对B细胞型、T细胞型淋巴瘤细胞株均敏感。Objective To investigate the sensitivity of seven human non-Hodgkin＇s lymphoma cell lines to bortezomib using in vitro MTT assay and provide theoretical basis for clinic.Methods The sensitivity of seven lymphoma cell lines to bortezomib was tested using in vitro MTT assay,and calculating the IC50.Results All the seven lymphoma cell lines were sensitive to bortezomib.The sensitivity of different cells to bortezomib varied.Conclusions Non-Hodgkin＇s lymphoma involving B-cell type and T-cell type both sensitive to bortezomib.

关 键 词：BZM 非霍奇淋巴瘤细胞株 MTT 

分 类 号：R733.1[医药卫生—肿瘤]